Dulaglutide

Generic Name: Dulaglutide

Brand Names: Trulicity

Drug Type: Biotech

CAS Number: 923950-08-7

Unique Ingredient Identifier: WTT295HSY5

Background: Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.

Indication: Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Associated Conditions: Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus

Clinical Trials

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

Phase 4

Completed

Conditions: Overweight
Healthy Volunteers
Diabetes Mellitus, Type 2
Obesity

Interventions: Drug: Semaglutide
Drug: Dulaglutide

First Posted Date: 2019-12-06

Last Posted Date: 2022-11-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 104

Registration Number: NCT04189848

Locations: 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: LY3437943
Drug: Dulaglutide

First Posted Date: 2019-10-29

Last Posted Date: 2021-01-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72

Registration Number: NCT04143802

Locations: 🇺🇸
Clinical Trials of Texas, Inc., San Antonio, Texas, United States
🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
PRA International, Lenexa, Kansas, United States

and more 1 locations

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Tirzepatide
Drug: Dulaglutide

First Posted Date: 2019-03-04

Last Posted Date: 2022-04-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 636

Registration Number: NCT03861052

Locations: 🇯🇵
Medical Corporation Chiseikai Tokyo Center Clinic, Chuo-ku, Tokyo, Japan
🇯🇵
Ikebukuro Metropolitan Clinic, Toshima-ku, Tokyo, Japan
🇯🇵
IHL Shinagawa East One Medical Clinic, Minato-ku, Tokyo, Japan

and more 43 locations

Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables

Phase 4

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Dulaglutide
Drug: Aspart insulin
Drug: Metformin
Drug: Glargine
Drug: Repaglinide

First Posted Date: 2019-01-31

Last Posted Date: 2019-01-31

Lead Sponsor: University of Palermo

Target Recruit Count: 92

Registration Number: NCT03824002

Locations: 🇮🇹
Internal Medicine Ward, University of Palermo, Palermo, Italy

Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients

Phase 4

Terminated

Conditions: Stress Hyperglycemia

Interventions: Drug: Dulaglutide Injection
Other: Saline Injection

First Posted Date: 2018-11-15

Last Posted Date: 2024-05-30

Lead Sponsor: Emory University

Target Recruit Count: 28

Registration Number: NCT03743025

Locations: 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Emory Hospital Midtown, Atlanta, Georgia, United States

A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Dulaglutide Pen
Drug: Semaglutide Pen

First Posted Date: 2018-10-30

Last Posted Date: 2020-04-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 312

Registration Number: NCT03724981

Locations: 🇺🇸
Long Beach Center for Clinical Research, Long Beach, California, United States
🇺🇸
Palm Harbor Medical Associates, Palm Harbor, Florida, United States
🇺🇸
Georgia Clinical Research, Snellville, Georgia, United States

and more 11 locations

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Phase 3

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Efpeglenatide
Drug: Dulaglutide
Drug: Background therapy Metformin

First Posted Date: 2018-09-26

Last Posted Date: 2021-11-01

Lead Sponsor: Sanofi

Target Recruit Count: 908

Registration Number: NCT03684642

Locations: 🇺🇸
Investigational Site Number 8400009, Los Angeles, California, United States
🇺🇸
Investigational Site Number 8400059, Skokie, Illinois, United States
🇺🇸
Investigational Site Number 8400061, Boston, Massachusetts, United States

and more 42 locations

Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes

Phase 2

Completed

Conditions: Adult Subjects With Type1Diabetes and Insulin Microsecretion

Interventions: Drug: Placebo
Drug: Dulaglutide

First Posted Date: 2018-09-12

Last Posted Date: 2021-07-08

Lead Sponsor: Hospices Civils de Lyon

Target Recruit Count: 45

Registration Number: NCT03668470

Locations: 🇫🇷
Service d'Endocrinologie, Maladies Métaboliques et Nutrition,CHU Nantes,Hôpital Nord Laennec,Bd Jacques-Monod,Saint-Herblain, NANTES cedex 1, France
🇫🇷
Service d'Endocrinologie, Maladies Métaboliques et Nutrition, CHU Grenoble, Hopital de la Tronche, La Tronche, France
🇫🇷
Département d''Endocrinologie, Diabétologie, Nutrition ; CHU Montpellier ; Hôpital Lapeyronie, Avenue du Doyen Giraud, Montpellier 5, France

and more 4 locations